Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 18/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4360652 | 0.93 | AGPAT2 (1.00) | AGPAT2ALDH1A1CDK9 | |
| SCHEMBL4372065 | 0.90 | AGPAT2 (0.89) | AGPAT2ALDH1A1CDK9 | |
| SCHEMBL13622456 | 0.88 | AGPAT2 (0.86) | AGPAT2ALDH1A1CDK9 | |
| SCHEMBL4366528 | 0.87 | AGPAT2 (0.84) | AGPAT2ALDH1A1CDK9 | |
| SCHEMBL4360685 | 0.86 | AGPAT2 (0.82) | AGPAT2ALDH1A1CDK9 | |
| SCHEMBL4359668 | 0.85 | AGPAT2 (0.79) | AGPAT2ALDH1A1CDK9 | |
| SCHEMBL4363416 | 0.84 | AGPAT2 (0.83) | AGPAT2ALDH1A1CDK9 | |
| SCHEMBL13622491 | 0.84 | AGPAT2 (0.77) | AGPAT2ALDH1A1CDK9 | |
| SCHEMBL4362325 | 0.82 | AGPAT2 (0.74) | AGPAT2ALDH1A1CDK9 | |
| SCHEMBL13622457 | 0.82 | AGPAT2 (1.00) | AGPAT2ALDH1A1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618968-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618968-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7291616-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291616-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 35/4885ALDH1A1 827/4885CDK9 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.